News | April 25, 2024
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
A significant proportion of healthcare professionals still tend to favor branded drugs
Doxycycline Capsules, 40 mg is indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients
Aurigene.AI is an end-to-end solution for small molecule drug discovery
Hepatitis B infects over 40 million people in India
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
More than 10,000 scientific publications containing EUDRAGIT
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
The drug will target specific genetic mutations prevalent in certain types of cancers
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Subscribe To Our Newsletter & Stay Updated
